Profund Advisors LLC Purchases 7,645 Shares of Natera, Inc. (NASDAQ:NTRA)

Profund Advisors LLC raised its position in Natera, Inc. (NASDAQ:NTRA) by 33.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,487 shares of the medical research company’s stock after purchasing an additional 7,645 shares during the period. Profund Advisors LLC’s holdings in Natera were worth $1,483,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Brown Advisory Inc. bought a new position in Natera in the 1st quarter valued at $241,000. Sei Investments Co. boosted its holdings in Natera by 98.7% in the 1st quarter. Sei Investments Co. now owns 291,626 shares of the medical research company’s stock valued at $16,191,000 after purchasing an additional 144,843 shares during the period. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of Natera by 8.5% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 9,953 shares of the medical research company’s stock worth $553,000 after acquiring an additional 776 shares during the last quarter. Strs Ohio bought a new stake in shares of Natera during the 1st quarter worth $621,000. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Natera by 14.5% during the 2nd quarter. Exchange Traded Concepts LLC now owns 32,666 shares of the medical research company’s stock worth $1,590,000 after acquiring an additional 4,128 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on NTRA shares. Morgan Stanley dropped their price objective on shares of Natera from $70.00 to $68.00 and set an “overweight” rating for the company in a report on Friday, November 10th. Credit Suisse Group reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Natera in a report on Friday, August 4th. Sanford C. Bernstein started coverage on shares of Natera in a report on Thursday, September 28th. They set a “market perform” rating and a $48.00 price objective for the company. Raymond James raised shares of Natera from an “outperform” rating to a “strong-buy” rating and set a $68.00 price objective for the company in a report on Monday, November 13th. Finally, Piper Sandler lowered their price target on shares of Natera from $80.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $64.00.

Insider Buying and Selling at Natera

In other Natera news, insider Jonathan Sheena sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $59.07, for a total value of $295,350.00. Following the transaction, the insider now owns 489,746 shares in the company, valued at $28,929,296.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Steven Leonard Chapman sold 2,617 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $45.82, for a total value of $119,910.94. Following the transaction, the chief executive officer now owns 217,554 shares in the company, valued at $9,968,324.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Sheena sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $59.07, for a total transaction of $295,350.00. Following the completion of the transaction, the insider now owns 489,746 shares in the company, valued at approximately $28,929,296.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,591 shares of company stock worth $1,590,587. 9.42% of the stock is currently owned by company insiders.

Natera Stock Performance

Natera stock opened at $54.79 on Tuesday. The company has a quick ratio of 4.23, a current ratio of 4.37 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $6.58 billion, a PE ratio of -12.12 and a beta of 1.18. The firm has a fifty day simple moving average of $45.17 and a two-hundred day simple moving average of $49.02. Natera, Inc. has a twelve month low of $34.70 and a twelve month high of $63.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.01. Natera had a negative net margin of 50.50% and a negative return on equity of 72.98%. The firm had revenue of $268.30 million for the quarter, compared to analysts’ expectations of $259.27 million. During the same quarter in the previous year, the company earned ($1.25) earnings per share. The company’s revenue for the quarter was up 27.4% compared to the same quarter last year. Research analysts expect that Natera, Inc. will post -3.92 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.